 MINNEAPOLIS, June 8, 2021 PRNewswire -- Bio-Techne Corporation NASDAQ: TECH today announced it is joining the Cell and Gene Therapy Catapult process analytical technology PAT consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities. The consortium will assess the application and combination of multiple technologies for process analytics within the cell and gene therapy industry. 